The lag time between the end of a performance period in the Oncology Care Model (OCM) and the release of the full report from CMS, represents a challenge for practices looking to improve.
Practices participating in the Oncology Care Model (OCM) recently received the results from performance period 2, but they’re currently enrolling patients for performance period 5. This lag time between the end of a performance period and the release of the full report represents a challenge for practices looking to improve.
Marcus Neubauer, MD, chief medical officer of the US Oncology Network, noted that while he recognizes that the lag time is unavoidable, it does hamper the practices participating in OCM and makes it difficult to enact changes based on the results they get.
“In an ideal setting, you get real-time data, and you are continuously learning,” he said, but the reality is that there will always be a lag with claims data.
Charles Saunders, chief executive officer of Integra Connect, explained that it takes about 6 months before all of the claims are collected, and then there is another 3 months for CMS to analyze the data. This timeline means it can be almost a full year after a performance period before practices receive the report card for that period.
This lag time can be difficult when it comes to the Monthly Enhanced Oncology Services (MEOS) payments, he explained. For instance, the performance period report includes patients who are attributed to a practice but for whom there are no associated MEOS payments.
“That means you were attributed patients that you’ve never billed a MEOS payment for,” Saunders said. Practices have up to a year to bill, “but if the data that you’re getting is pretty close to a year, there’s just not much time to go in to recover those charges that you may have overlooked and not billed for.”
Another challenge with the lag time between when a period ends and when practices receive the report is that practices can have trouble pinpointing what they did almost a full year ago that caused the results they are now seeing.
While working with practices, Integra Connect has noticed the big question is: Why is this happening? Saunders said that practices that improve can sometimes be unsure of what is driving the improvement, while those that didn’t generate savings may have trouble understanding why.
“It’s just a fact that those results are delayed, but when you do get them it really is an opportunity to look at the data, learn where you’re doing particularly well on quality metrics, or not, and learn where you’re doing particularly well, or not, on some of the financial cost metrics,” Neubauer said.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More